<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923282</url>
  </required_header>
  <id_info>
    <org_study_id>AP-recAP-AKI-01-02</org_study_id>
    <nct_id>NCT04923282</nct_id>
  </id_info>
  <brief_title>Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects</brief_title>
  <official_title>A Double Blind, Randomized, Single Center, Single and Multiple Dose, Pharmacokinetic, Safety and Tolerability Study of Recombinant Human Alkaline Phosphatase (recAP) Administered Intravenously in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AM-Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AM-Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Phase 1 study to investigate the pharmacokinetics and to assess the safety and&#xD;
      tolerability of recAP after single and multiple intravenous doses in healthy Japanese&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double blind, parallel group, single-center trial, consisting of&#xD;
      a single dose part and a multiple dose part in 32 healthy Japanese subjects. Since all these&#xD;
      doses have been studied before and safety extensively evaluated in non-Japanese subjects and&#xD;
      no ethnic sensitivity is expected, the groups can be dosed in parallel.&#xD;
&#xD;
      Part A will have 3 parallel groups of 8 male subjects with N=6 on active and N=2 on placebo&#xD;
      per group. Following baseline assessments, a single dose of recAP will be administered by a&#xD;
      one-hour infusion followed by samplings for pharmacokinetic evaluation and routine safety&#xD;
      assessments.&#xD;
&#xD;
      Part B will have a single group of 8 male subjects with N=6 on active and N=2 on placebo.&#xD;
      Following baseline assessments, recAP will be dosed on Days 1, 2 and 3 by one-hour infusions&#xD;
      followed by samplings for pharmacokinetic evaluation and routine safety assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed recAP plasma concentration (Cmax) after single dose</measure>
    <time_frame>Single dose 9 days treatment phase</time_frame>
    <description>Blood collection for cmax evaluation daily from Day 1 to Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to attain maximum recAP serum concentration (Tmax) after single dose</measure>
    <time_frame>Single dose 9 days treatment phase</time_frame>
    <description>Blood collection for Tmax evaluation daily from Day 1 to Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) after single dose</measure>
    <time_frame>Single dose 9 days treatment phase</time_frame>
    <description>Blood collection for AUC evaluation daily from Day 1 to Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recAP elimination half-life ( t1/2) after single dose</measure>
    <time_frame>Single dose 9 days treatment phase</time_frame>
    <description>Blood collection for t1/2 evaluation daily from Day 1 to Day 9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed recAP plasma concentration (Cmax) after multiple doses</measure>
    <time_frame>Multiple doses 13 days treatment phase</time_frame>
    <description>Blood collection for cmax evaluation daily from Day 1 to Day 13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to attain maximum recAP serum concentration (Tmax) after multiple doses</measure>
    <time_frame>Multiple doses 13 days treatment phase</time_frame>
    <description>Blood collection for Tmax evaluation daily from Day 1 to Day 13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) after multiple doses</measure>
    <time_frame>Multiple doses 13 days treatment phase</time_frame>
    <description>Blood collection for AUC evaluation daily from Day 1 to Day 13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recAP elimination half-life ( t1/2) after multiple doses</measure>
    <time_frame>Multiple doses 13 days treatment phase</time_frame>
    <description>Blood collection for t1/2 evaluation daily from Day 1 to Day 13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) after single dose</measure>
    <time_frame>Single dose 9 days treatment phase</time_frame>
    <description>Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) after multiple doses</measure>
    <time_frame>Multiple doses 13 days treatment phase</time_frame>
    <description>Any untoward medical occurrence in a subject enrolled into a clinical study regardless of its causal relationship to study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 1-hour IV infusion of 0.8 mg/kg recAP or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 1-hour IV infusion of 1.6 mg/kg recAP or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 1-hour IV infusion of 3.2 mg/kg recAP or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>single 1-hour IV infusion of 0.8 mg/kg recAP</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>single 1-hour IV infusion of 1.6 mg/kg recAP</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>single 1-hour IV infusion of 3.2 mg/kg recAP</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo</arm_group_label>
    <arm_group_label>Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo</arm_group_label>
    <arm_group_label>Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo</arm_group_label>
    <arm_group_label>Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender : male&#xD;
&#xD;
          2. Age : 20-55 years, inclusive&#xD;
&#xD;
          3. Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive&#xD;
&#xD;
          4. Subjects must be Japanese by birth, have resided outside Japan &lt;10 years, have parents&#xD;
             and maternal and paternal grandparents who are Japanese, and primarily consume a&#xD;
             Japanese diet.&#xD;
&#xD;
          5. Resting supine blood pressure at screening showing no clinically relevant deviations&#xD;
             from normal as judged by the Principal Investigator.&#xD;
&#xD;
          6. Computerized (12-lead) ECG recording without signs of clinically relevant pathology or&#xD;
             showing no clinically relevant deviations.&#xD;
&#xD;
          7. All values for hematology and for clinical chemistry tests of blood and urine within&#xD;
             the normal range or showing no clinically relevant deviations as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          8. Ability and willingness to abstain from alcohol and tobacco products from 48 h prior&#xD;
             to entry in the clinical research center until discharge.&#xD;
&#xD;
          9. Easily accessible veins for venipuncture and catheter placing.&#xD;
&#xD;
         10. Willingness to sign the written informed consent form (ICF).&#xD;
&#xD;
         11. Subjects must agree to use adequate contraception when sexually active. This applies&#xD;
             for the time period between end of first administration and 14 days after the last&#xD;
             administration of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of clinically relevant pathology.&#xD;
&#xD;
          2. History of relevant drug and/or food allergies.&#xD;
&#xD;
          3. Subject has a history of clinically significant abnormalities or of any illness that,&#xD;
             in the opinion of the study investigator, might confound the results of the study or&#xD;
             poses an additional risk to the subject by their participation in the study.&#xD;
&#xD;
          4. Use of medication, except for acetaminophen (paracetamol), which is allowed up to 3&#xD;
             days before entry into the clinical research center (after that time the use of a&#xD;
             limited amount of acetaminophen is permitted after consultation with the Principal&#xD;
             Investigator).&#xD;
&#xD;
          5. Subject is mentally or legally incapacitated, has significant emotional problems at&#xD;
             the time of screening visit or expected during the conduct of the study or has a&#xD;
             history of a clinically significant psychiatric disorder over the last year.&#xD;
&#xD;
          6. Participation in a drug study within 60 days prior to drug administration.&#xD;
&#xD;
          7. Donation of more than 500 mL of blood within 60 days prior to drug administration.&#xD;
             Donation of more than 1.5 liters of blood (for men) in the 10 months preceding the&#xD;
             start of this study&#xD;
&#xD;
          8. Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily.&#xD;
&#xD;
          9. History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products).&#xD;
&#xD;
         10. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids,&#xD;
             barbiturates, benzodiazepines, tricyclic antidepressants) and/or alcohol breath test&#xD;
             at Screening and/or Pre-Dose.&#xD;
&#xD;
         11. Intake of more than 14 units of alcohol per week (one unit of alcohol equals&#xD;
             approximately 250 mL of beer, 100 mL of wine/Japanese Sake or 35 mL of spirits).&#xD;
&#xD;
         12. Positive screen on hepatitis B surface antigen (HBsAg), anti-hepatitis C virus&#xD;
             (anti-HCV) or anti-human immunodeficiency virus (anti-HIV)-1 or anti-HIV-2 or HIV-1/2&#xD;
             antigen.&#xD;
&#xD;
         13. Illness within 5 days prior to (the first) drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelies Legters</last_name>
    <role>Study Director</role>
    <affiliation>AM-Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeshi Kurosawa</last_name>
    <phone>+818011570442</phone>
    <email>clinicalTrialInformation@cmic.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>P-One Clinic, Keikokai Medical Corporation</name>
      <address>
        <city>Tokyo</city>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Furihata</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

